vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Sintx Technologies, Inc. (SINT). Click either name above to swap in a different company.
Sintx Technologies, Inc. is the larger business by last-quarter revenue ($290.0K vs $169.0K, roughly 1.7× Aligos Therapeutics, Inc.). On growth, Sintx Technologies, Inc. posted the faster year-over-year revenue change (-46.5% vs -72.1%). Over the past eight quarters, Sintx Technologies, Inc.'s revenue compounded faster (-35.0% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Sintx Technologies, Inc. is an advanced materials company specializing in R&D and manufacturing of high-performance silicon nitride and other technical ceramic products. It serves key segments including medical implants, aerospace & defense, industrial wear components, and electric vehicle applications, with core markets across North America, Europe and Asia-Pacific.
ALGS vs SINT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $290.0K |
| Net Profit | — | $-2.2M |
| Gross Margin | — | 64.8% |
| Operating Margin | — | -799.3% |
| Net Margin | — | -763.8% |
| Revenue YoY | -72.1% | -46.5% |
| Net Profit YoY | 75.8% | -30.7% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $290.0K | ||
| Q3 25 | $741.0K | $208.0K | ||
| Q2 25 | $965.0K | $151.0K | ||
| Q1 25 | $311.0K | $369.0K | ||
| Q4 24 | $606.0K | $542.0K | ||
| Q3 24 | $1.3M | $799.0K | ||
| Q2 24 | $1.1M | $859.0K | ||
| Q1 24 | $694.0K | $687.0K |
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-31.5M | $-3.5M | ||
| Q2 25 | $-15.9M | $-2.3M | ||
| Q1 25 | $43.1M | $-2.3M | ||
| Q4 24 | $-82.2M | $-1.7M | ||
| Q3 24 | $-19.3M | $-6.2M | ||
| Q2 24 | $5.1M | $-2.2M | ||
| Q1 24 | $-34.9M | $-886.0K |
| Q4 25 | — | 64.8% | ||
| Q3 25 | — | 44.7% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | 33.3% | ||
| Q4 24 | — | 71.6% | ||
| Q3 24 | — | 73.7% | ||
| Q2 24 | — | 73.9% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | — | -799.3% | ||
| Q3 25 | -3827.4% | -1613.0% | ||
| Q2 25 | -1924.0% | -1764.9% | ||
| Q1 25 | -6187.5% | -645.8% | ||
| Q4 24 | -3393.2% | -319.6% | ||
| Q3 24 | -1610.5% | -802.0% | ||
| Q2 24 | -2489.5% | -315.5% | ||
| Q1 24 | -3176.7% | -465.4% |
| Q4 25 | — | -763.8% | ||
| Q3 25 | -4256.0% | -1701.4% | ||
| Q2 25 | -1643.8% | -1535.1% | ||
| Q1 25 | 13854.7% | -621.1% | ||
| Q4 24 | -13556.1% | -312.7% | ||
| Q3 24 | -1540.7% | -780.9% | ||
| Q2 24 | 477.0% | -256.6% | ||
| Q1 24 | -5023.5% | -129.0% |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | $-3.04 | $-3.46 | ||
| Q2 25 | $-1.53 | $-0.91 | ||
| Q1 25 | $-2.11 | $-1.29 | ||
| Q4 24 | $-13.10 | $17.04 | ||
| Q3 24 | $-3.07 | $-6.96 | ||
| Q2 24 | $0.81 | $-3.61 | ||
| Q1 24 | $-5.58 | $-21.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $2.9M |
| Total Assets | $88.5M | $9.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $4.1M | ||
| Q3 25 | $99.1M | $6.3M | ||
| Q2 25 | $122.9M | $4.3M | ||
| Q1 25 | $137.9M | $6.5M | ||
| Q4 24 | $56.9M | $3.6M | ||
| Q3 24 | $74.9M | $4.8M | ||
| Q2 24 | $94.5M | $4.6M | ||
| Q1 24 | $112.7M | $5.8M |
| Q4 25 | $53.5M | $2.9M | ||
| Q3 25 | $71.8M | $4.1M | ||
| Q2 25 | $101.9M | $4.0M | ||
| Q1 25 | $116.4M | $6.1M | ||
| Q4 24 | $-29.0M | $3.9M | ||
| Q3 24 | $50.1M | $5.6M | ||
| Q2 24 | $67.2M | $8.8M | ||
| Q1 24 | $59.8M | $9.9M |
| Q4 25 | $88.5M | $9.5M | ||
| Q3 25 | $109.8M | $11.4M | ||
| Q2 25 | $134.7M | $9.2M | ||
| Q1 25 | $150.7M | $11.4M | ||
| Q4 24 | $70.1M | $9.4M | ||
| Q3 24 | $88.4M | $11.3M | ||
| Q2 24 | $108.8M | $15.3M | ||
| Q1 24 | $127.9M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-2.3M |
| Free Cash FlowOCF − Capex | — | $-2.4M |
| FCF MarginFCF / Revenue | — | -822.8% |
| Capex IntensityCapex / Revenue | — | 14.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-2.3M | ||
| Q3 25 | $-24.3M | $-2.5M | ||
| Q2 25 | $-15.5M | $-2.4M | ||
| Q1 25 | $-20.9M | $-1.3M | ||
| Q4 24 | $-18.4M | $-1.1M | ||
| Q3 24 | $-20.1M | $-2.6M | ||
| Q2 24 | $-19.5M | $-2.2M | ||
| Q1 24 | $-22.7M | $-2.7M |
| Q4 25 | — | $-2.4M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-2.6M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | — | -822.8% | ||
| Q3 25 | — | -1250.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -368.6% | ||
| Q4 24 | — | -234.3% | ||
| Q3 24 | — | -323.0% | ||
| Q2 24 | — | -299.7% | ||
| Q1 24 | — | -423.1% |
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 40.4% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 16.0% | ||
| Q4 24 | — | 26.9% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 25.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
